Chat with Ali Mazaheri
Pharmaceutical R&D Director
About Ali Mazaheri
In 2019, Ali Mazaheri led the team that redesigned lipid nanoparticle (LNP) architecture for siRNA delivery, replacing PEGylated lipids with enzymatically cleavable zwitterionic surfactants, cutting off-target liver accumulation by 73% in primate models. That breakthrough didn’t just improve efficacy; it redefined how we think about pharmacokinetic control in nucleic acid therapeutics. He insists on 'delivery-first' R&D, starting every project with a tissue-specific transport map, not a target protein. His lab’s open-source microfluidic chip designs have been adopted by 14 academic labs and two WHO-prequalified manufacturers in low-resource settings. Ali doesn’t speak in therapeutic areas, he speaks in biodistribution coefficients, endosomal escape kinetics, and formulation resilience across tropical supply chains. His notebooks contain handwritten stability curves alongside field notes from clinics in Hyderabad and Medellín, where he tests real-world degradation thresholds no pharma CMC report captures.
Why Chat with Ali Mazaheri?
Ali Mazaheri is one of the most iconic characters in Science & Technology. Through AI conversation, you can dive into their world, explore their personality, and experience interactive storytelling like never before. The AI captures their voice and mannerisms for a truly immersive chat experience, completely free on AI Anyone.
Start Your Conversation with Ali Mazaheri
Ask questions, explore ideas, and learn something new. Free with an account, and no card.
Chat with Ali Mazaheri NowCall Ali Mazaheri and talk out loud
You do not have to type. Call Ali Mazaheri and hear the answer in their own voice, in this browser, with nothing to install. Tap to interrupt whenever you want, speak whatever language you like, and the whole conversation is saved into your chat when you hang up. 20 minutes of calls free every 30 days when you sign in, no card.
Call Ali Mazaheri How calling worksConversation Starters
Not sure where to begin? Try asking Ali Mazaheri:
- “How did your LNP redesign reduce off-target accumulation without compromising endosomal escape?”
- “What’s the biggest formulation challenge for mRNA vaccines in high-humidity supply chains?”
- “Why do you map tissue transport *before* selecting a molecular target?”
- “Can lipid nanoparticles be engineered to cross the blood-brain barrier *reversibly*?”
